Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

In conclusion, this study showcases the need to study the influence of different CAR architectures based on an identical scFv individually. It indicates that current scFv-based anti-BCMA CAR with clinical utility may already be at their functional optimum regarding the known structural variations of the scFv linker.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research